Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease

Abstract

Adalimumab was effective in providing sustained clinical remission. In patients in clinical remission, the C-reactive protein level at 2 months, endoscopic response at 6 months, or inflammatory phenotype and short disease duration could be considered as good predictors of efficacy.

Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease

“…Of those reviewed in further detail, 22 were excluded because of study design, 5 were excluded because they included patients either in endoscopic and/or clinical remission and 11 were excluded because they either did not perform endoscopic assessment for MH or endoscopic mucosal assessment was performed outside of the pre‐specified follow‐up time interval . Eight studies where corresponding authors no longer had access to the data, declined to provide data of interest, or did not respond to our queries were also excluded . One study was excluded where the corresponding authors responded, yet there was still insufficient data .…”

Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease

“…14 The contribution of shorter duration of CD to MH also seems consistent with the results of prior investigations showing the clinical efficacy of ADA in patients with CD. 15,16 However, we are unable to conclude that patients with clinically active CD are candidates for MH with ADA treatment, because we did not evaluate small bowel lesions of the entire small bowel in our subjects. The higher CDAI found in the present study may be a consequence of ileal lesions in the proximal small bowel of terminal ileum and complications, which are in fact unrelated to the response of colonic lesions to ADA.…”

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease

“…For long-term prognosis of ADA therapy, Echarri et al 28 reported that there are no significant differences between combination therapy and monotherapy with regard to clinical remission and mucosal healing at 12 and 24 months. Thus, other treatment options are needed to improve the prognosis and prevent ADA-LOR.…”